<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994015</url>
  </required_header>
  <id_info>
    <org_study_id>PDGENE-PF</org_study_id>
    <nct_id>NCT04994015</nct_id>
  </id_info>
  <brief_title>Parkinson's Foundation PD GENEration Genetic Registry</brief_title>
  <official_title>Parkinson's Foundation PD GENEration Genetic Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parkinson's Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fulgent Genetics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parkinson's Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Parkinson's Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development of a central repository for PD-related genomic data for future research.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to develop a central repository for PD-related genomic data by&#xD;
      individuals who consent to deposit their data and bank their residual DNA obtained through&#xD;
      clinical genetic testing for future research use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will undergo genetic counseling service post-genetic testing either locally or through central services.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Parkinson's related genetic mutations in an convenience cohort</measure>
    <time_frame>6 months</time_frame>
    <description>Identify people with Parkinson's who have genetic mutations to advance basic science and clinical research.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Educating people with Parkinson's of their genetic mutation status through genetic testing and counseling</measure>
    <time_frame>6 months</time_frame>
    <description>People who are informed of their genetic status may be empowered to learn more about their disease and participant in clinical research.</description>
  </primary_outcome>
  <enrollment type="Anticipated">15000</enrollment>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lab Assay for seven genetic variants for Parkinson's Disease</intervention_name>
    <description>Counseling provided to participant by site clinician/physician/genetic counselor.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study Population 1: PWP (open for recruitment)&#xD;
&#xD;
               1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's&#xD;
                  Disease: probable diagnosis.&#xD;
&#xD;
               2. Willingness to undergo genetic testing, and choose to be informed of genetic&#xD;
                  testing results for GBA, LRRK2 and 5 additional PD related genes (SNCA, VPS35,&#xD;
                  PRKN, PINK-1, PARK7).&#xD;
&#xD;
               3. Capacity to give full informed consent in writing or electronically, and have&#xD;
                  read and signed the informed consent forms (ICFs) based on site clinician's&#xD;
                  determination.&#xD;
&#xD;
               4. Able to perform study activities (including completion of either online,&#xD;
                  in-person or paper surveys).&#xD;
&#xD;
        Study Population 2: People at risk of developing PD (not open for recruitment)&#xD;
&#xD;
        1. Family members of Study Population 1 may be invited to participate in the study if&#xD;
        confirmatory genetic testing is deemed necessary by the genetic testing laboratory.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy,&#xD;
             progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome),&#xD;
             including that due to medications, metabolic disorders, encephalitis, cerebrovascular&#xD;
             disease, or normal pressure hydrocephalus.&#xD;
&#xD;
          2. Individuals who have received a blood transfusion within the past 3 months.&#xD;
&#xD;
          3. Individuals who have active hematologic malignancies such as lymphoma or leukemia.&#xD;
&#xD;
          4. Individuals who have had a bone marrow transplant within the past 5 years.&#xD;
&#xD;
          5. Under the age of 18&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Beck, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parkinson's Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kamalini Ghosh, MS</last_name>
    <phone>1-800-473-4636</phone>
    <email>kghosh@parkinson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robbie Cummins</last_name>
      <email>robbie.cummins@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Jeanne Feuerstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aventura Neurologists-Visionary Investigators Network</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Palmquist</last_name>
      <email>jpalmquist@visionaryinvestigators.com</email>
    </contact>
    <investigator>
      <last_name>Julie Schwartzbard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morehouse Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sherline Sauveur</last_name>
      <email>ssauveur@msm.edu</email>
    </contact>
    <investigator>
      <last_name>Chantale Branson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Ramsey</last_name>
      <email>kaitlyn.ramsey@steward.org</email>
    </contact>
    <investigator>
      <last_name>Eleni Okeanis Vaou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (BIDMC)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Babcock</last_name>
      <email>hbabcock@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>David Simon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Northwest Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Bixby Sanchez, MS</last_name>
      <email>mbixby@inwresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jason Aldred, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 26, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT04994015/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

